|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemotherapy for gastric cancer显示文摘变形胃的癌症仍然是非药品疾病。没有生活妥协的质量,辩解的化疗被表明了延长幸存。单个代理人的许多和联合被证实了在变形疾病的治疗活跃。客观反应率为综合化学疗法为单个代理人的治疗和 30-60% 从 10-30%。阶段 II 和 III 研究的结果在这篇论文以及新药的潜在的功效被考察。为有局部性的疾病的病人,助手和 neoadjuvant 化疗和放射治疗的角色被讨论。辅助化疗上的大多数研究没能表明一个幸存优点,因此,它没在大多数中心被看作标准疗法。辅助免疫化疗在朝鲜和日本根本上被开发了。有 OK-432 的阶段 III 试用的元分析建议那免疫化疗可以改进病人的幸存与 curatively resected 胃的癌症。基于美国的结果团体之间 0116 学习,手术后的 chemoradiation 与 resected 在病人作为标准照顾被接受了在北美洲的胃的癌症。然而,结果被病人们经历了的事实有点惊讶不到推荐 D1 淋巴节点解剖和复发的模式建议没有任何效果,积极效果在微变形疾病上源于本地放射疗法。Neoadjuvant 化疗或 chemoradiation 治疗仍然保持试验性,但是几阶段 II 学习正在显示出有希望的结果。阶段 III 试用被需要。 | Javier Sastre Jose Angel García-Saenz Eduardo Díaz-Rubio | 2006 | World Journal of Gastroenterology2006，12，2： | 22 |
| 2 | Role of cetuximab in first-line treatment of metastatic colorectal cancer显示文摘The treatment of metastatic colorectal cancer(mCRC)has evolved considerably in the last decade,currently allowing most mCRC patients to live more than two years.Monoclonal antibodies targeting the epidermal growth factor receptor(EGFR)and vascular endothelial growth factor play an important role in the current treatment of these patients.However,only antibodies directed against EGFR have a predictive marker of response,which is the mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS).Cetuximab has been shown to be effective in patients with KRAS wild-type mCRC.The CRYSTAL study showed that adding cetuximab to FOLFIRI(regimen of irinotecan,infusional fluorouracil and leucovorin)significantly improved results in the first-line treatment of KRAS wildtype mCRC.However,results that evaluate the efficacy of cetuximab in combination with oxaliplatin-based chemotherapy in this setting are contradictory.On the other hand,recent advances in the management of colorectal liver metastases have improved survival in these patients.Adding cetuximab to standard chemotherapy increases the response rate in patients with wild-type KRAS and can thus increase the resectability rate of liver metastases in this group of patients.In this paper we review the different studies assessing the efficacy of cetuximab in the first-line treatment of mCRC. | Miguel Jhonatan Sotelo Beatriz García-Paredes Carlos Aguado Javier Sastre Eduardo Díaz-Rubio | 2014 | World Journal of Gastroenterology2014，20，15： | 7 |
| 3 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?显示文摘Fluoropyrimidines play a central role in the first-line treatment of metastatic colorectal cancer.Our aim was to review whether capecitabine was a safer,non-inferior,economically superior and more convenient alternative to 5-fluorouracil.Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin,irinotecan,or biological drugs-and has been found to have comparable efficacy and safety profiles.Furthermore,pharmacoeconomic data and patients’preferences for oral chemotherapy further favor capecitabine.Therefore,capecitabine appears to be an effective and safe alternative to fluorouracil in the first-line treatment of metastatic colorectal cancer. | Carlos Aguado Beatriz García-Paredes Miguel Jhonatan Sotelo Javier Sastre Eduardo Díaz-Rubio | 2014 | World Journal of Gastroenterology2014，20，20： | 4 |
| 4 | Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute pancreatitis显示文摘Acute pancreatitis is an inflammation of the pancreas that may lead to systemic inflammatory response syndrome and death due to multiple organ failure. Acinar cells, together with leukocytes, trigger the inflammatory cascade in response to local damage of the pancreas. Amplification of the inflammatory cascade requires up-regulation of proinflammatory cytokines and this process is mediated not only by nuclear factor κB but also by chromatinmodifying complexes and chromatin remodeling. Among the different families of histone acetyltransferases, the p300/CBP family seems to be particularly associated with the inflammatory process. cAMP activates gene expression via the cAMP-responsive element (CRE) and the transcription factor CRE-binding protein (CREB). CREB can be phosphorylated and activated by different kinases, such as protein kinase A and MAPK, and then it recruits the histone acetyltransferase co-activator CREB-binding protein (CBP) and its homologue p300. The recruitment of CBP/p300 and changes in the level of histone acetylation are required for transcription activation. Transcriptional repression is also a dynamic and essential mechanism of down-regulation of genes for resolution of inflammation, which seems to be mediated mainly by protein phosphatases (PP1, PP2A and MKP1) and histone deacetylases(HDACs) .Class HDACs are key transcriptional regulators whose activities are controlled via phosphorylationdependent nucleo/cytoplasmic shuttling. PP2A is responsible for dephosphorylation of class HDACs, triggeringnuclear localization and repression of target genes, whereas phosphorylation triggers cytoplasmic localization leading to activation of target genes. The potential benefit from treatment with phosphodiesterase inhibitors and histone deacetylase inhibitors is discussed. | Javier Escobar Javier Pereda Alessandro Arduini Juan Sastre Juan Sandoval Luis Aparisi Gerardo López-Rodas Luis Sabater | 2010 | World Journal of Gastrointestinal Pharmacology and Therapeutics2010，1，3： | 2 |
| 5 | Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function显示文摘 | Jon Zugazagoitia Aránzazu Manzano Javier Sastre Jose María Ladero Javier Puente Eduardo Díaz-Rubio | 2013 | Clinical and Translational Oncology2013，，2： | 2 |
| 6 | Irinotecan in the treatment of elderly patients with advanced colorectal cancer显示文摘 | Javier Sastre Javier Puente Jose A. García-Saenz Eduardo Díaz-Rubio | 2008 | Critical Reviews in Oncology and Hematology2008，，3： | 1 |
| 7 | Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study显示文摘 | Javier Sastre Enrique Aranda Bartomeu Massutí Jose Tabernero Manuel Chaves Albert Abad Alfredo Carrato Juan José Reina Bernardo Queralt Auxiliadora Gómez-Espa?a Encarnación González-Flores Fernando Rivera Ferrán Losa Teresa García Pedro Sanchez-Rovira Inm | 2008 | Critical Reviews in Oncology and Hematology2008，，2： | 1 |
| 8 | Effect of Simultaneous Inhibition of TNF-α Production and Xanthine Oxidase in Experimental Acute Pancreatitis: The Role of Mitogen Activated Protein Kinases显示文摘 | Javier Pereda Luis Sabater Norberto Cassinello Luis Gómez-Cambronero Daniel Closa Emma Folch-Puy Luis Aparisi Julio Calvete Miguel Cerdá Salvador Lledó José Vi?a Juan Sastre | 2004 | Annals of Surgery2004，，1： | 1 |
| 9 | Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab显示文摘 | Pablo Gajate Javier Sastre Inmaculada Bando Teresa Alonso Lourdes Cillero Julian Sanz Trinidad Caldés Eduardo Díaz-Rubio | 2012 | Clinical Colorectal Cancer2012，，4： | 1 |
| 10 | Time Used for Orthodontic Surgical Treatment of Dentofacial Deformities in White Patients显示文摘 | Pedro Martos Diaz Raul Gonzalez Garcia Luis Naval Gias Armando Aguirre-Jaime Jesús Sastre Pérez Maria Mancha de la Plata Esther Villa Navarro Francisco Javier Diaz Gonzalez | 2010 | Journal of Oral and Maxillofacial Surgery2010，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员